The United Kingdom and the United States have reached a landmark bilateral deal that will preserve no duties on UK drug exports entering the American market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to boost funding on medicines through the National Health Service (NHS). This move guarantees that duties on these vital products will remain at zero for a timeframe of the next three years.
This deal follows earlier threats to hike import taxes on branded pharmaceutical products, with potential rates floated reaching one hundred percent.
"This agreement with the UK bolsters the international landscape for new treatments and brings much-needed balance to American-British drug exports," an announcement said.
Economic Impact
Drugs are one of the UK's most significant export categories to the US, which is by far the primary market for leading companies like GSK and AstraZeneca.
Trade data show that in the 12 months prior to September, the UK exported pharmaceutical products totaling billions to the US. This value accounted for a significant portion of all goods exports in that period.
"This agreement secures work, boosts capital expenditure and paves the way for the UK to establish itself as a global hub for medical research," the Business and Trade Secretary remarked.
Specific UK Commitments
The pact includes several key commitments from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to double overall health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must return to the NHS to stay within budget will be restricted at fifteen percent. Last year, refunds were more than twenty percent.
Recent Tensions
The pact takes place against a long-running dispute between the sector and the UK government over spending levels and approval rates.
The disagreement were exacerbated by arguments that American patients were paying a premium for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
One official acknowledged that the NHS had to invest a greater share on drugs, noting that its budget allocation on drugs had declined as a percentage of its resources over the past decade.
